Literature DB >> 22783805

A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom.

R S Camilleri1, M Scully, M Thomas, I J Mackie, R Liesner, W J Chen, K Manns, S J Machin.   

Abstract

BACKGROUND: ADAMTS13 mutations play a role in thrombotic thrombocytopenic purpura (TTP) pathogenesis.
OBJECTIVES: To establish a phenotype-genotype correlation in a cohort of congenital TTP patients. PATIENTS/
METHODS: Clinical history and ADAMTS13 activity, antigen and anti-ADAMTS13 antibody assays were used to diagnose congenital TTP, and DNA sequencing and in vitro expression were performed to identify the functional effects of the ADAMTS13 mutations responsible.
RESULTS: Seventeen (11 novel) ADAMTS13 mutations were identified in 17 congenital TTP patients. All had severely reduced ADAMTS13 activity and antigen levels at presentation. Six patients with pregnancy-associated TTP and six patients with childhood TTP were homozygous or compound heterozygous for ADAMTS13 mutations located in the metalloprotease (MP), cysteine-rich, spacer and/or distal thrombospondin type 1 domains. The adults had TTP precipitated by pregnancy, and had overall higher antigen levels (median, 30 ng mL(-1) ; range, < 10-57 ng mL(-1) ) than the children (median, 14 ng mL(-1) ; range, < 10-40 ng mL(-1)). Presentation in the neonatal period was associated with more intensive treatment requirements. The two neonates with the most severe phenotype had mutations in the first thrombospondin type 1 motif of ADAMTS13 (p.R398C, p.R409W, and p.Q436H). Using transfected HEK293T cells, we have shown that p.R398C and p.R409W block ADAMTS13 secretion, whereas p.Q436H allows secretion at reduced levels.
CONCLUSIONS: This study confirms the heterogeneity of ADAMTS13 defects and an association between ADAMTS13 genotypes and TTP phenotype.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22783805     DOI: 10.1111/j.1538-7836.2012.04852.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  12 in total

1.  The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Kejian Zhang; Fanggeng Zou; Benjamin Laskin; Christopher E Dandoy; Kasiani C Myers; Adam Lane; Jaroslav Meller; Mario Medvedovic; Jenny Chen; Stella M Davies
Journal:  Blood       Date:  2015-11-24       Impact factor: 22.113

2.  The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.

Authors:  Martin Bommer; Manuela Wölfle-Guter; Stephan Bohl; Florian Kuchenbauer
Journal:  Dtsch Arztebl Int       Date:  2018-05-11       Impact factor: 5.594

3.  ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.

Authors:  Ashish Goel; V Raghupathy; G J Amirtharaj; Aaron Chapla; Aparna Venkatraman; Banumathi Ramakrishna; Anup Ramachandran; Nihal Thomas; K A Balasubramanian; Ian Mackie; Elwyn Elias; Chundamannil E Eapen
Journal:  Indian J Gastroenterol       Date:  2017-10-05

4.  ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.

Authors:  Erica Rurali; Federica Banterla; Roberta Donadelli; Elena Bresin; Miriam Galbusera; Sara Gastoldi; Flora Peyvandi; Mary Underwood; Giuseppe Remuzzi; Marina Noris
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-04       Impact factor: 8.237

5.  TTP or complement-mediated TMA or both? A rare diagnosis and report of a novel plasminogen gene variant.

Authors:  Nishant R Tiwari; Sankalp Arora; Aditya G Tolat; Saad Paul Shaheen; Vivek R Sharma
Journal:  Ann Hematol       Date:  2021-07-16       Impact factor: 3.673

6.  ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies.

Authors:  Galit Sarig
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

7.  Upshaw-Schulman syndrome-associated ADAMTS13 variants possess proteolytic activity at the surface of endothelial cells and in simulated circulation.

Authors:  Anton Letzer; Katja Lehmann; Christian Mess; Gesa König; Tobias Obser; Sven Peine; Sonja Schneppenheim; Ulrich Budde; Stefan W Schneider; Reinhard Schneppenheim; Maria A Brehm
Journal:  PLoS One       Date:  2020-05-04       Impact factor: 3.240

8.  The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017.

Authors:  Hendrika A van Dorland; Magnus Mansouri Taleghani; Kazuya Sakai; Kenneth D Friedman; James N George; Ingrid Hrachovinova; Paul N Knöbl; Anne Sophie von Krogh; Reinhard Schneppenheim; Isabella Aebi-Huber; Lukas Bütikofer; Carlo R Largiadèr; Zuzana Cermakova; Koichi Kokame; Toshiyuki Miyata; Hideo Yagi; Deirdra R Terrell; Sara K Vesely; Masanori Matsumoto; Bernhard Lämmle; Yoshihiro Fujimura; Johanna A Kremer Hovinga
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

9.  De Novo Mutation of the ADAMTS13 Gene with Mesenteric Ischemia in an Infant with Congenital Thrombotic Thrombocytopenic Purpura.

Authors:  Ibrahim Alharbi; Sarah Alqarni; Wed Khayyat; Amirah Almatrafi
Journal:  Case Rep Hematol       Date:  2021-07-06

10.  Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing.

Authors:  Teresa Fidalgo; Patrícia Martinho; Catarina S Pinto; Ana C Oliveira; Ramon Salvado; Nina Borràs; Margarida Coucelo; Licínio Manco; Tabita Maia; M João Mendes; Rafael Del Orbe Barreto; Irene Corrales; Francisco Vidal; M Letícia Ribeiro
Journal:  Res Pract Thromb Haemost       Date:  2017-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.